| Note: MSIF related links may have been removed from the host website. We apologized for the inconvenience. December 29, 2007 Vaccinating against the hepatitis B virus does not appear to be associated with the risk of developing multiple sclerosis in childhood, according to study done in France. {Arch Pediatr Adolesc Med. 2007;161(12):1176-1182] www.jamamedia.org. BioMS Medical Corp. announced that the company has received a recommendation from an independent Data Safety Monitoring Board to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. MBP8298 is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein that is administer intravenously. http://www.biomsmedical.com/product_overview.asp Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage and should be consider as symptomatic. Higher disability and cervical cord damage represent a significant risk factor for RLS in MS patients. [Multiple Sclerosis 2008;14: 86—93]. http://msj.sagepub.com/cgi/content/abstract/14/1/86 A study reports that HLA-DRB1 *01 acts as an independent modifier the disease progression. This allele appears to attenuate the progressive disability that characterizes MS in the long term. The observation was doubly replicated in a Sardinian benign and malignant patients and a cohort of affected sibling pairs discordant for HLA-DRB1 *01 . http://www.pnas.org/cgi/content/abstract/104/52/20896 Scientists based at Jerusalem's Hadassah University Hospital have broken new ground in the field of stem cell research by injecting 26 multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients. with therapeutic quantities of cultured adult stem cells harvested from their own hip marrow. After extraction, the cells were subjected to an in vitro cleansing, multiplication and chemical 'tagging', being re-injected into the patients via lumbar puncture. The trials were the first in the world to use this type of stem cells. No adverse effects were noted, and the patients displayed anecdotal improvements in clinical symptoms, leading the way for further developments in forthcoming clinical trials. This result is considered highly experimental since it lacks a control group.http://www.israel21c.org/bin/en.jsp?enDispWho=Articles% 5El1889&enSearchQueryID=48&enPage=BlankPage&enDisplay=view&enDispWhat=object&enVers ion=0&enZone=Health& November 14, 2007 A study found that this new MRI techinique using high-field proton magnetic resonance spectroscopy in patients with clinically isolated syndromes can be use as a predictive tool of who would go on to develop MS. [Neuroradiology. 2007 Nov 3] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17982745&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum BRIGHT study reported that Patients with relapsing-remitting multiple sclerosis (MS) treated with 250 mcg Betaseron (interferon beta-1b) experienced less injection site pain and fewer injection site reactions than those treated with 44 mcg Rebif. The BRIGHT study is a multicenter (76 centers), international (13 countries), non-randomized, prospective, observational study comparing the tolerability of Betaseron with Rebif with 454 patients. [Bayer HealthCare Pharmaceuticals PressRelease in earthtimes.org] http://www.earthtimes.org/articles/show/news_press_release,217975.shtml The authors explain a possible role of Epstein-Barr virus infection in multiple sclerosis. [J Exp Med. 2007 Nov 5] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17984305&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum The role of optical coherence tomography (OCT) in multiple sclerosis was examined by an expert panel consensus that concluded the technique may be very useful in future trials. [J Neurol Sci. 2007 Dec 15;263(1-2):3-14. Epub 2007 Jul 27]. http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17673257&ordinalpos=4&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Researchers found that a year after a community-based course to teach effective method of managing fatigue in MS had terminated, the techniques learned were still effective in managing the fatigue. [Int J Rehabil Res. 2007 Dec;30(4):305-313] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17975450&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Oct. 29,2007 Eye Scanning Device Detects MS Nervous System Damage National MS Society Research update http://www.nationalmssociety.org/site/PageServer? pagename=HOM_RES_research_2007oct18 In an Italian study, vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. [Multiple Sclerosis, Vol. 13, No. 9, 1200-1202 (2007)] http://msj.sagepub.com/cgi/content/abstract/13/9/1200 Large scale study was unable to show superiority of Betaferon 500 mcg compared to Betaferon 250 mcg and Copaxone. Betaferon 250 mcg is still the optimal Betaferon dose based on high efficacy and excellent tolerability. http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews%5btt_news% 5d=12123&tx_ttnews%5bbackPid%5d=36&cHash=5e8c70c707 The U.S. Food and Drug Administration (FDA) has issued a warning in connection with the drug Provigil because of dangerous side effects; among those found are Stevens-Johnson Syndrome (red rash), hallucinations, anxiety and suicidal thoughts. FDA recomends to talk and see to your doctor regarding this news. http://www.news-medical.net/?id=31791 Oct. 11, 2007 Survey found that although no differences were noted in terms of disease severity and diagnostic history, findings indicated that people treated at MS Comprehensive Care Centers had better access to health care services and perceived their health care experiences more positively than those who never received MS care from a Comprehensive Care Centers. http://www.mscare.org/cmsc/Current-Issue.html A study wants to establish a test battery that could be used as an outcome to succinctly and sufficiently measure fatigue in MS patients with mild to moderate disability. [International Journal MS Care. 2007;9:118–125] http://www.mscare.org/cmsc/Current-Issue.html Analysis showed that compared to patients with no family history of MS, familial MS patients had significantly more destructed lesions, and significantly lower volume of whole brain, white matter and gray matter, as well as other indications of greater brain degradation. http://www.medindia.net/news/MS-That-Runs-In-Families-Appears-More-Severe-Than-Non-Familial- MS-27655-2.htm Sirtris pharmaceuticals' oral drug SRT501 shown to be neuroprotective in laboratory animals with a model of optic neuritis. http://www.genengnews.com/news/bnitem.aspx?name=24426455 Mayo Clinic researchers presented a study in which human antibody leads to repair of myelin sheath in laboratory mouse study of multiple sclerosis and related disorders. http://www.eurekalert.org/pub_releases/2007-10/mc-alt100407.php September 20, 2007 Studies of clinical histories of children less than 16 years old with MS in France found that parental smoking at home increased the risk of occurrence of MS which was also dependent on duration of exposure. [Brain. 2007 Oct;130(Pt 10):2589-95. Epub 2007 Sep 7] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17827175&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Using a new MRI techniques, researchers have found that the spinal cord grey matter in people with relapsing MS was affected by the disease and that this damage could contribute to disability; even if no lesion was visible in the MRI. [Arch Neurol. 2007 Sep;64(9):1302-5] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17846269&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Recent studies have indicated that brain atrophy is more closely associated with cognitive impairment in MS than conventional MRI lesion measures. http://www.msif.org/en/global_ms_network/ms_news/ms_and_cognition.html September 1, 2007 Cannabis (marihuana) use was linked to an increase risk of psychosis in later life. (pdf format) http://www.medscape.com/viewarticle/560746?src=mp An analysis of the clinical history of persons with relapsing remitting MS and secondary progressive, treated with disease modifying drugs(DMD) in Nova Scotia, Canada during 1988 through 2004 showed that the use of DMD effectively delayed the progression of disability in 90% people with relapsing remitting MS. It was not as as effective in the people with secondary progressive. http://www.neurology.org/cgi/content/abstract/01.wnl.0000271884.11129.f3v1 Biopartners have submitted to the EMEA (European Agency for Evaluation of Medicinal Products) application for authorization of Biferonex (interferon beta-1a). This product represent an optimized interferon beta treatment solution because it is Ph neutral and human serum albumin free. This formulation has a low incidence of neutralizing antibodies and its neutral Ph minimizes skin reactions. It will be used in persons with relapsing remitting MS. http://www.pharmaceutical-business-review.com/article_news.asp?guid=45DBE14A-C077-41E9- 8F11-37FCD8D80B75 A reanalysis of MRI from 90 people with MS relapsing-remitting discovered that the presence of more than 10 T2 lesions doubles the risk of developing secondary progressive. [European Journal of Neurology 14 (11), 1210–1215] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01915.x A study examines the variability of cannabis to treat effectively pain in people with MS. They will try to explain pharmacologically that the reason for this variation is due to the pathogenesis of the pain and the receptors involve. [European Journal of Neurology 14 (10), 1162–1169] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01903.x July 22,2007 New study shows that people that were treated with Natalizumab have higher incidence of post- lumbar punction headache. [Arch Neurol. 2007;64:1055-1056] http://archneur.ama-assn.org/cgi/content/extract/64/7/1055 Prevelance of autoimmune thyroid disordes show up in persons with MS in Spain. [European Journal of Neurology 14 (9), 1048–1052] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01882.x July 7, 2007 Disputing earlier findings, new study reports men and women with MS transmit the disease equally to their children http://www.nationalmssociety.org/site/PageServer?pagename=HOM_RES_research_2007jun29 June 29,2007 Genetics. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. [Int Rev Neurobiol. 2007;79:521-35] http://www.ncbi.nlm.nih.gov/sites/entrez? db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17531857&query_hl=15&itool=pubmed_ docsum A study find ethnic and socio-economic disparities in the management of multiple sclerosis–related bladder symptoms. [NEUROLOGY 2007;68:1971-1978] http://www.neurology.org/cgi/content/abstract/68/23/1971 The Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score is used as an early prediction of long term evolution of MS. It may be useful both to identify patients who are candidates for early or for more aggressive therapies and to improve the design and analysis of clinical therapeutic trials and of observational studies. [J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):757-9. Epub 2007 Jan 12] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17220286&ordinalpos=9&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Investigators find a direct relation between reduce brain volume and higher lesion volume in MRI and a higher degree disability. [Neurology. 2007 Jun 12;68(24):2059-65] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17562826&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum The MS Society in UK looks into the Unproven Goat Serum treatment "Aimspro". http://www.mssociety.org.uk/news_events/news/press_releases/goats_guardian.html Authors find that compare to adult onset MS, childhood onset MS take longer to reach the progressive stage of the disease and are slower to accumulate irreversible disability. [N Engl J Med. 2007 Jun 21;356(25):2603-13] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17582070&ordinalpos=1&itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum June 3, 2007 The Latin American Association for MS has a new website. http://www.ulasem.org May 9, 2007 Retinal nerve fiber layer atrophy and retinal periphlebitis are associated with disease activity,that includes new relapses and disability. [NEUROLOGY 2007;68:1488-1494] http://www.neurology.org/cgi/content/abstract/68/18/1488 Interferon-beta therapy may reduce MS activity by suppression or depletion of autoreactive, pro inflammatory T-cells. http://www.msif.org/en/research/research_news/reduces_cd4_and.html April 19.2007 A study finds that Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. [NEUROLOGY 2007;68:1299-1304] http://www.neurology.org/cgi/content/abstract/68/16/1299 They published a study that reviewed patient visits to family practitioners, neurologists or internists between 1998 and 2004 across the United States and found that the majority of the persons with MS are not taking treatment to slow disease progression. Specifically "about 62 percent of patients visiting neurologists and 92 percent seen by family practitioners/internists were not using inmuno- modulatory agents (IMAs).Treatment with IMAs is known to reduce the frequency of relapses and slow disease progression." http://www.huliq.com/18643/multiple-sclerosis-patients-not-receiving-medications-to-slow-disease- progression A study finds high prevalence of restless legs syndrome in multiple sclerosis. Restless leg syndrome is also associated with higher disability. [European Journal of Neurology 14 (5), 534–539] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01740.x March 25, 2007 Clinical trial of cannabis-based medicine may be useful for treatment of spasticity in MS.[European Journal of Neurology 14 (3), 290–296] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2006.01639.x? journalCode=ene&volume=14&issue=3 Randomized double-blind, dose comparison study of glatiramer acetate in relapsing-remitting MS shows that a dose of 40 mg was safe, well tolerated and may be more effective than the currently approved 20mg daily dose in reducing MRI activity and clinical relapses.[NEUROLOGY 2007;68:939- 944] http://www.neurology.org/cgi/content/abstract/68/12/939 March 9 2007 Some links may have been removed- this will be corrected soon. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. http://www.neurology.org/cgi/content/abstract/68/10/779 From the MSIF brief news dated March 6, 2007 A study found minimal changes in cognitive disorders during a 10 year clinical trial in persons with relapsing multiple sclerosis. http://www.msif.org/en/research/research_news/minimal_changes.html Here is an article that reviews the most important research done on tremor, a symptom that shows up in 25-60% of MS persons. http://www.msif.org/en/research/research_news/tremor_in_multip.html Contrary to popular belief that MS is a white matter disease, this article reviews studies up to date that shows gray matter involvement at the beginning of the disease with early atrophy. http://www.msif.org/en/research/research_news/gray_matter_invo.html From the MSIF brief news dated January 16, 2007 In San Francisco, USA from January 16 to 19, 2007 the National MS Society with support of the Canadian MS Society will host an international stem cell summit titled "Stem Cells and MS: Prospects and Strategies". Leading stem cell research investigators from across the world will exchange information and share knowledge to identify strategies for research in this area. http://www.nationalmssociety.org/stemcell.asp They identify more severe disability in North Africans compared to Europeans with MS in France. Not only the MS has a more aggressive progressive disease in this population but starts at an earlier age. http://www.msif.org/en/research/research_news/more_severe_disa.html After following more than 25,000 people with prior Mononucleosis for 30 years in Denmark, the authors reported an increased risk of developing MS. The risk of multiple sclerosis persist at least 30 years after the infection. Little is known about the characteristics of the association. http://www.msif.org/en/research/research_news/mononucleosis.html December 12, 2006 A report on the use of the electrophysiological measure auditory P300 and its usefulness to predict which people with MS would benefit from modafanil as treatment for their fatigue in this open label study. http://www.msif.org/en/research/research_news/p300_and_treatme.html This study found areas of loss of Grey matter in people with MS. The pattern of loss was different to that seen in normal aging and the authors suggest this could be due to the underlying white matter lesions. http://www.msif.org/en/research/research_news/focal_cortical_a.html This article is a review of what is known of MS and how interferon and other immune modulating treatments may work. http://www.msif.org/en/research/research_news/facts_hopes_and.html November 23,2006 A study on baclofen, (a muscle relaxant) administered directly into the spinal fluid for the treatment of spasticity, showed that patients on this treatment had improved sleep, but that their ability to breath normally overnight was not affected. The authors conclude that the drug may act directly on the spinal nerves with not affect on the brain. http://www.msif.org/en/research/research_news/effect_of_intrat.html Preliminary data show beneficial effects of interferon in ocular disease such as Behcet disease and multiple sclerosis-associated uveitis in terms of visual acuity, intraocular inflammation activity, and chronic macular edema. http://www.msif.org/en/research/research_news/interferon_thera.html There has been increase interest on work interventions due to an increase number of persons with chronic disease abandoning the work force. This study presents a analysis of nine studies that focused on vocational rehabilitation interventions in order to decide which approaches are fruitful. http://www.msif.org/en/research/research_news/how_can_we_help.html A small recent study in MS patients with chronic low-back pain, did not find a statistically significant benefit from the use of Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) machines. http://www.msif.org/en/research/research_news/efficacy_of_tran.html A descriptive study in families of people with MS, found that autoimmune diseases are common. This suggest a general susceptibility to this type of disease, and in families where this was the case, there was a link with the CTLA4 gene. http://www.msif.org/en/research/research_news/clustering_of_au.html October 24, 2006 The FDA approves the use of Interferon beta 1-b, Betaseron, for cases of individuals who have experienced a clinically isolated syndrome (a single clinical event that is indicative of demyelination, such as inflammation of the optic nerve or an episode of numbness on one side) and have MRI (magnetic resonance imaging) features consistent with MS. http://www.nationalmssociety.org/research-2006Oct23.asp From the MSIF brief news dated October 17, 2006 This multi-centre randomized placebo-controlled trial showed that cannabis extract reduces the rate of episodes of urinary urge incontinence in people with MS but not the results of urodynamic studies. http://www.msif.org/en/research/research_news/the_effect_of_ca.html A trial showed that treating people with clinically isolated syndromes with interferon beta1-b delays the onset of MS at two years. Ongoing work is looking at whether this effect is sustained at five years http://www.msif.org/en/research/research_news/beta1b_delays_c.html. A small uncontrolled study looked at 13 people with worsening moderately severe relapsing remitting and secondary progressive MS which was not responsive to conventional treatments. It found that high dose cyclophosphamide was safe and of some benefit in stabilizing disease progression. http://www.msif.org/en/research/research_news/moderate_to_seve.html Multiple sclerosis research took center stage at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held September 27-30, 2006, in Madrid. Results were presented from numerous clinical trials, indicating the potential within the MS pipeline. Pediatric studies, including seven from investigators at three of six Pediatric MS Centers of Excellence, established and funded by the US MS Society were reported. Several researchers reported on programs to improve the care and quality of life of people with MS. A sample of these is available on the link to the US MS Society news item below. http://www.nationalmssociety.org/research-2006Oct13.asp For more information on the Paediatrics MS Centers of Excellence: http://www.nationalmssociety.org/news_pediatricMScenters.asp Rest of "06 news can be found in the Spanish section named Ultimas Noticias. |
Maria A Reyes-Velarde, MD, MPH hablemosdeeem.com |
Latest News
HABLEMOS DE
ESCLEROSIS MULTIPLE
©2001maria a. reyes-velarde
ESCLEROSIS MULTIPLE
©2001maria a. reyes-velarde
Disclaimer:
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE, INACCURACY OR INCOMPLETENESS OF
INFORMATION, USE OF THIS INFORMATION OR RESULTS ARISING FORM THE USE OF IT, COMPUTER VIRUSES, MALICIOUS
CODE, LOSS OF DATA, COMPATIBILITY ISSUES, OR OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY
FOR ANY DIRECT, INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING LOST
PROFITS, LOST DATA. COST TO PROCURE REPLACEMENT SERVICES OR GOODS, OR BUSINESS OPPORTUNITIES) ARISING
OUT OF YOUR ACCESS TO OR USE OF OUR SITE, OR ANY OTHER LINK WE PROVIDE TO ANOTHER SITE, OR ANY ACTS,
OMISSIONS, DEFECTS, SECURITY BREACHES, OR DELAYS, REGARDLESS OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE OR LOSS. EACH PERSON HAS TO CONSULT ANY INFORMATION WITH
HIS/HER PHYSICIAN.
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE, INACCURACY OR INCOMPLETENESS OF
INFORMATION, USE OF THIS INFORMATION OR RESULTS ARISING FORM THE USE OF IT, COMPUTER VIRUSES, MALICIOUS
CODE, LOSS OF DATA, COMPATIBILITY ISSUES, OR OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY
FOR ANY DIRECT, INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING LOST
PROFITS, LOST DATA. COST TO PROCURE REPLACEMENT SERVICES OR GOODS, OR BUSINESS OPPORTUNITIES) ARISING
OUT OF YOUR ACCESS TO OR USE OF OUR SITE, OR ANY OTHER LINK WE PROVIDE TO ANOTHER SITE, OR ANY ACTS,
OMISSIONS, DEFECTS, SECURITY BREACHES, OR DELAYS, REGARDLESS OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE OR LOSS. EACH PERSON HAS TO CONSULT ANY INFORMATION WITH
HIS/HER PHYSICIAN.
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |